Search clinical trials for: Aflibercept,

Total 480 results

Bayer
Regeneron Pharmaceuticals

Completed

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)

Wet Age-related Macular Degeneration

Germany
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions (NEWTON)

Macular Edema With Central Retinal Vein Occlusions

United States
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Bayer

Completed

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (BELUGA)

Neovascular Age-related Macular Degeneration

Belgium
Bayer

Completed

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America (AQUILA)

Macular Degeneration

Mexico, Argentina, Colombia, Costa Rica
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study for Collection of Aflibercept Data in Routine Practice (CODEX)

Eye Diseases

France
Bayer
Regeneron Pharmaceuticals

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) (JPMS-CRVO)

Retinal Vein Occlusion

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients (VEGA)

Glaucoma, Neovascular

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Diabetic Macular Edema (DME) | Age-related Macular Degeneration (AMD) | Central Retinal Vein Occlusion (CRVO)

Canada
Jeffrey S Heier
Regeneron Pharmaceuticals

Unknown

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD (PRO-CON)

Age-Related Macular Degeneration

United States
4D Molecular Therapeutics

Recruiting

4D-150 in Patients With Diabetic Macular Edema

Diabetic Retinopathy | Diabetic Macular Edema

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections (RAZORBILL)

Neovascular Age-Related Macular Degeneration

Spain, Italy, Germany, Canada, Ireland
Seoul National University Hospital

Completed

Visual Function Change in Wet Age-related Macular Degeneration Patients With Better Baseline Visual Acuity

Age-Related Macular Degeneration

Korea, Republic of
Bayer

Recruiting

The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema

Visual Impairment | Neovascular Age-related Macular Degeneration (nAMD) | Diabetic Macula Edema (DME)

Germany, Canada, Denmark, France, Italy, Saudi Arabia, Switzerland, Australia, Finland, Netherlands, Sweden, Norway, United Arab Emirates, Japan, United Kingdom
Sandoz

Completed

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

Neovascular Age-related Macular Degeneration (nAMD)

United States
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)

Retinopathy of Prematurity (ROP)

Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
Amin El Sayed Nawar
Tanta University

Completed

Use of Ziv Aflibercept in Different Retinal Diseases

Central Retinal Vein Occlusion With Macular Edema

Egypt
Regeneron Pharmaceuticals

Terminated

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD) (CAPELLA)

Neovascular Age-Related Macular Degeneration

United States, Japan
Association for Innovation and Biomedical Research...
European Vision Institute Clinical Research Network

Completed

Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy (ATLANTIC)

Polypoidal Choroidal Vasculopathy

Portugal, Spain
Changhua Christian Hospital

Completed

Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan (OIVAEGFFAMDIT)

AMD

Taiwan
Bayer
Regeneron Pharmaceuticals

Completed

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye (ARIES)

Macular Degeneration

Spain, Hungary, United Kingdom, Australia, Italy, Canada, France, Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied (VENERA)

Glaucoma, Neovascular

Japan
Al Hadi Hospital

Completed

Aflibercept With and Without Micropulse Laser in Diabetic Macular Edema (MPL)

Diabetic Macular Edema

Kuwait
Sorlandet Hospital HF

Completed

Mechanisms of Retinal Revascularization and Clinical Indicators of Neovascular AMD Relapse

Wet Macular Degeneration

Norway
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

China
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (ALTAIR)

Wet Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Eylea Post Marketing Surveillance(PMS)

Macular Degeneration

Korea, Republic of
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (PERSEUS-IT)

Wet Macular Degeneration

Italy
Bayer
Regeneron Pharmaceuticals

Completed

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD (RAINBOW)

Wet Macular Degeneration

France
Bayer

Completed

A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV) (REALM)

Myopic Choroidal Neovascularization

Canada
Bayer
Regeneron Pharmaceuticals

Completed

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) (REALE)

Macular Degeneration

Spain
Yeungnam University College of Medicine

Unknown

Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion

Branch Retinal Vein Occlusion With Macular Edema

Korea, Republic of
Bayer

Completed

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. (AQUA)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, France, Czechia, Germany, Hungary, Italy, Lithuania
Bayer
RTI Health Solutions

Completed

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Macular Degeneration

France, Germany, Spain, Italy, United Kingdom
Bayer
Regeneron Pharmaceuticals

Completed

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Wet Macular Degeneration

Japan
Sohag University

Recruiting

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Diabetic Macular Edema

Egypt
Bayer

Completed

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema (VISION-AF)

Diabetic Macular Edema

India
The Emmes Company, LLC
National Eye Institute (NEI); University of Wisconsin, Madison; Milton S. Hershey...

Completed

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) (SCORE2)

Central Retinal Vein Occlusion

United States
University Hospital Inselspital, Berne

Terminated

Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study) (AVOCT)

Diabetic Macular Edema

Switzerland
Chiang Mai University

Recruiting

Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept

Polypoidal Choroidal Vasculopathy

Thailand
M. Ali Khan, MD
University of California, Los Angeles; Southeastern Retina Associates; Eye Associates...

Recruiting

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair (PREVENT-PVR)

Proliferative Vitreoretinopathy | Retinal Detachment With Multiple Breaks, Unspecified Eye

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) (TALON)

Age-related Macular Degeneration

United States, Austria, Czechia, Italy, Taiwan, Belgium, Germany, Australia, Israel, Canada, France, Spain, Korea, Republic of, United Kingdom, Portugal, Netherlands, Sweden, Argentina, Malaysia, Switzerland
Northern California Retina Vitreous Associates
Regeneron Pharmaceuticals

Completed

The Endurance 1 Trial (Endurance)

Diabetic Macular Edema
Arshad Khanani
Genentech, Inc.

Completed

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Southeast Retina Center, Georgia

Completed

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab (ROTATED)

Diabetic Macular Edema

United States
Centre Oscar Lambret
Sanofi

Terminated

Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR). (PULSAR)

Metastatic Colorectal Cancer

France
Novartis Pharmaceuticals

Completed

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration (TIDE AMD)

Wet Age-Related Macular Degeneration

Germany

3

Subscribe